Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy.
Advanced techniques for detecting kinase inhibitors are in demand due to limitations of traditional approaches. Here, we used a fluorescence resonance energy transfer (FRET)-based kinase assay, a sensitive fluorescence turn-on biosensing platform, to identify a Polo-like kinase 1 (PLK1) inhibitor. The assay was developed with the Z'-Lyte™ FRET-peptide and PLK1 kinase purified from a baculovirus expression system. Using PLK1 inhibitors, sensitivity and efficiency of this FRET-based PLK1 kinase assay were compared to those of radioisotope-based and immunoblot-based assays. Although the inhibitory activity of BI 2536 against PLK1 kinase in each assay was almost the same, the FRET-based PLK1 kinase assay was much easier, faster, safer, and more convenient than a radioisotope-based assay or an immunoblot-based traditional kinase assay. From our findings, we suggest that a FRET-based PLK1 kinase assay is an advanced tool which overcomes the limitations of previous traditional kinase assays to detect kinase inhibitors for the development of anticancer drugs.
Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea.
Sol-Bi
SB
Shin
Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea.
Sang-Uk
SU
Woo
Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea.
Young-Joo
YJ
Lee
Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea hsyim@hanyang.ac.kr.
Hyungshin
H
Yim
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry*; D001562:Benzimidazoles / Q000737:chemistry; D001681:Biological Assay; D014408:Biomarkers, Tumor / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D031541:Fluorescence Resonance Energy Transfer; D005456:Fluorescent Dyes / Q000737:chemistry; D019833:Genistein / Q000737:chemistry; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D007313:Insecta; D010455:Peptides / Q000737:chemistry; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D011621:Pteridines / Q000737:chemistry; D011868:Radioisotopes / Q000737:chemistry; D013876:Thiophenes / Q000737:chemistry; D000090324:Tumor Protein, Translationally-Controlled 1; D000097869:Polo-Like Kinase 1
D000970:Antineoplastic Agents; D001562:Benzimidazoles; D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D005456:Fluorescent Dyes; D019833:Genistein; D005982:Glutathione Transferase; D010455:Peptides; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D011621:Pteridines; D011868:Radioisotopes; D013876:Thiophenes; D000090324:Tumor Protein, Translationally-Controlled 1; D000097869:Polo-Like Kinase 1; C518477:BI 2536; C561573:GSK 461364
BI 2536; FRET; PLK1; immunoblot; kinase assay; radioisotope